Skip to main content
. Author manuscript; available in PMC: 2020 Dec 21.
Published in final edited form as: Gastroenterology. 2020 Mar 26;159(1):139–147. doi: 10.1053/j.gastro.2020.03.039

Figure 3.

Figure 3.

Kaplan-Meier estimates of CD disease progression based on endoscopic remission at the end of the CALM study with 95% CIs. Disease progression was defined as any major adverse outcome: composite of new internal fistula/abscess, stricture, perianal fistula/abscess, CD hospitalization, or CD surgery since end of the CALM study.